Candel Therapeutics (CADL)
(Delayed Data from NSDQ)
$5.96 USD
-0.21 (-3.40%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $5.96 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Candel Therapeutics, Inc. has a market cap of $309.13M, which represents its share price of $6.17 multiplied by its outstanding shares number of 50.10M. As a small-cap company, CADL's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
CADL 5.96 -0.21(-3.40%)
Will CADL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CADL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CADL
Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know
Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?
CADL: What are Zacks experts saying now?
Zacks Private Portfolio Services
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer
Best Momentum Stocks to Buy for May 19th
New Strong Buy Stocks for May 19th
Other News for CADL
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference | CADL ...
Candel Therapeutics (CADL) Secures EMA Orphan Status for Pancreatic Cancer Treatment | CADL ...
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of ...
Candel Therapeutics receives EMA Orphan Designation for CAN-2409
ASML, J B Hunt Transport And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session